Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (1-10 of 204) with videos related to

Pageof 21
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2015
Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!Tawanda Gumbo
Nature Genetics|June 27, 2013
Biological variability and the emergence of multidrug-resistant tuberculosisTawanda Gumbo
Antimicrobial Agents and Chemotherapy|January 21, 2010
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variabilityTawanda Gumbo
Current Opinion in Infectious Diseases|November 3, 2007
Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategiesTawanda Gumbo
Current Opinion in Drug Discovery & Development|January 5, 2008
Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapyTawanda Gumbo
Idcases|July 17, 2023
Safety and tolerability of long-term use of omadacycline in the treatment of <i>Mycobacterium abscessus</i> infectionsShashikant Srivastava, Tawanda Gumbo
Open Forum Infectious Diseases|August 14, 2023
Comment on "Long-term Safety and Tolerability of Omadacycline for the Treatment of <i>Mycobacterium abscessus</i> Infections"Shashikant Srivastava, Tawanda Gumbo
Therapeutics and Clinical Risk Management|August 30, 2008
Anidulafungin in the treatment of invasive fungal infectionsKathryn Sabol, Tawanda Gumbo
Future Microbiology|April 30, 2011
Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium aviumDevyani Deshpande, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|October 13, 2010
An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the futureJotam Pasipanodya, Tawanda Gumbo
Pageof 21

Showing results (1-10 of 204) with videos related to

Sort By:
Pageof 21
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2015
Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!Tawanda Gumbo
Nature Genetics|June 27, 2013
Biological variability and the emergence of multidrug-resistant tuberculosisTawanda Gumbo
Antimicrobial Agents and Chemotherapy|January 21, 2010
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variabilityTawanda Gumbo
Current Opinion in Infectious Diseases|November 3, 2007
Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategiesTawanda Gumbo
Current Opinion in Drug Discovery & Development|January 5, 2008
Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapyTawanda Gumbo
Idcases|July 17, 2023
Safety and tolerability of long-term use of omadacycline in the treatment of <i>Mycobacterium abscessus</i> infectionsShashikant Srivastava, Tawanda Gumbo
Open Forum Infectious Diseases|August 14, 2023
Comment on "Long-term Safety and Tolerability of Omadacycline for the Treatment of <i>Mycobacterium abscessus</i> Infections"Shashikant Srivastava, Tawanda Gumbo
Therapeutics and Clinical Risk Management|August 30, 2008
Anidulafungin in the treatment of invasive fungal infectionsKathryn Sabol, Tawanda Gumbo
Future Microbiology|April 30, 2011
Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium aviumDevyani Deshpande, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|October 13, 2010
An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the futureJotam Pasipanodya, Tawanda Gumbo
Pageof 21